{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=71", "query": { "intervention": "Open Label Extension Study", "page": 71 }, "page_size": 10 }, "pagination": { "page": 71, "page_size": 10, "total_count": 2086, "total_pages": 209, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=72&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=70&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T21:07:51.804Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00216255", "title": "EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Persistent Developmental Stuttering" ], "interventions": [ { "name": "Pagoclone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 120, "start_date": "2005-04", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2012-09-03", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 16, "location_summary": "Peoria, Arizona • Orange, California • Riverside, California + 13 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216255" }, { "nct_id": "NCT07253285", "title": "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo cagrilintide", "type": "DRUG" }, { "name": "Placebo semaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "8 Years to 18 Years" }, "enrollment_count": 460, "start_date": "2026-01-08", "completion_date": "2033-09-20", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 34, "location_summary": "Escondido, California • Hollywood, Florida • Jacksonville, Florida + 29 more", "locations": [ { "city": "Escondido", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07253285" }, { "nct_id": "NCT00487435", "title": "An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain", "Osteoarthritis", "Low Back Pain" ], "interventions": [ { "name": "Tapentadol (CG5503) Extended Release (ER)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1166, "start_date": "2007-06", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 118, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Mobile, Alabama + 115 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487435" }, { "nct_id": "NCT03614234", "title": "Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "pegunigalsidase alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chiesi Farmaceutici S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2018-11-13", "completion_date": "2026-04-13", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03614234" }, { "nct_id": "NCT07043634", "title": "A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bioavailability Heathy Volunteers" ], "interventions": [ { "name": "FDC (24 mg ER torsemide and 30 mg Spironolactone) without food", "type": "COMBINATION_PRODUCT" }, { "name": "FDC (24 mg ER torsemide and 30 mg Spironolactone) with food", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Sarfez Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 24, "start_date": "2025-06-15", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 1, "location_summary": "Vienna, Virginia", "locations": [ { "city": "Vienna", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07043634" }, { "nct_id": "NCT03355209", "title": "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lennox Gastaut Syndrome" ], "interventions": [ { "name": "ZX008 0.2 or 0.8 mg/kg/day", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "2 Years to 35 Years" }, "enrollment_count": 296, "start_date": "2017-11-27", "completion_date": "2024-05-23", "has_results": true, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 30, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03355209" }, { "nct_id": "NCT04572685", "title": "Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia Patients" ], "interventions": [ { "name": "Paliperidone Palmitate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Luye Pharma Group Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2020-01-22", "completion_date": "2020-08-20", "has_results": false, "last_update_posted_date": "2020-11-09", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 1, "location_summary": "Berlin, New Jersey", "locations": [ { "city": "Berlin", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572685" }, { "nct_id": "NCT06260709", "title": "A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transthyretin Amyloid Cardiomyopathy (ATTR CM)" ], "interventions": [ { "name": "NNC6019-0001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 88, "start_date": "2024-02-20", "completion_date": "2030-02-09", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Los Angeles, California • Stanford, California + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06260709" }, { "nct_id": "NCT03781414", "title": "Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Transplant Rejection" ], "interventions": [ { "name": "CFZ533", "type": "BIOLOGICAL" }, { "name": "Tacrolimus - MMF - corticosteroids", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 129, "start_date": "2019-10-07", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 9, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03781414" }, { "nct_id": "NCT00116116", "title": "DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "AIDS" ], "interventions": [ { "name": "efavirenz, stavudine extended release, lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2002-03", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2011-04-26", "last_synced_at": "2026-11-11T21:07:51.804Z", "location_count": 10, "location_summary": "Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116116" } ] }